Skip to main content
Premium Trial:

Request an Annual Quote

HBIO s Revenues Stay Flat, Earnings Shrink in Q2

NEW YORK, July 30 (GenomeWeb News) - Harvard Bioscience yesterday reported flat revenues and dwindling earnings for the second quarter.

 

The company's revenues for the quarter totaled $22.5 million, compared to $22.4 million during the same period last year.

 

"In the first half of this year our Genomic Solutions product lines produced disappointing results that have dragged down our overall growth and profitability so far this year," said CEO Chane Granziano in a company statement. "We have made significant changes in managing this business that we believe...will return this business to profitability and growth."

 

R&D expenses for the quarter remained flat at $1.7 million, similar to last year's costs.

 

HBIO's net income was $0.3 million, or $.01 per share, down from $0.74 million, or $.02 per share, for last year's quarter.

 

As of  June 30, HBIO had $10.5 million in cash and cash equivalents.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.